Elevance Health (ELV) hikes 2024 earnings outlook, shares climb
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Elevance (ELV) PT Raised to $575 at RBC Capital
April 19, 2024 6:46 AM EDTRBC Capital analyst Ben Hendrix raised the price target on Elevance (NYSE: ELV) to $575.00 (from $574.00) while maintaining a Outperform rating.
The analyst comments "Elevance again outperforms against a difficult managed care backdrop, with utilization across the benefit businesses tracking in line with expectations.... More
Elevance (ELV) PT Raised to $605 at UBS
April 19, 2024 6:36 AM EDTUBS analyst AJ Rice raised the price target on Elevance (NYSE: ELV) to $605.00 (from $585.00) while maintaining a Buy rating.
The analyst comments "ELV provided a few more details around its recently announced CDR partnership, noting that the care delivery entity will start... More
Elevance (ELV) PT Raised to $600 at Wells Fargo
April 19, 2024 5:57 AM EDTWells Fargo analyst Stephen Baxter raised the price target on Elevance (NYSE: ELV) to $600.00 (from $557.00) while maintaining a Overweight rating.
The analyst comments "ELV's 1Q24 results were strong and earnings quality appears high. Story remains fairly clean from our perspective. Continued growth... More
Elevance Health Inc. (ELV) Tops Q1 EPS by 16c, tops guidance
April 18, 2024 6:01 AM EDTElevance Health Inc. (NYSE: ELV) reported Q1 EPS of $10.64, $0.16 better than the analyst estimate of $10.48. Revenue for the quarter came in at $42.3 billion versus the consensus estimate of $42.47 billion.
GUIDANCE:
Elevance Health Inc. sees FY2024 EPS at greater of $37.20, versus... More
